Search Filter

Drug See All +

Supported Studies Areas of Interest

This page allows you to search through the current areas of interest for ViiV Supported studies.

Results Section
The results section lists the current Areas of Interest by drug, title, and a brief description. By clicking on the "Title" hyperlink, you will find more information regarding the Core Focus Area, Example Research Questions, and Study Parameters, including Populations of Interest and Geographical Regions.

Adding to Your List
Click on the "Add to List +" button to link your proposal with this Area of Interest (AOI). You can select multiple AOIs if appropriate.

Each drug will include a "General" Area of Interest (AOI) option for proposals that do not align with the existing AOIs. While ViiV Healthcare prioritizes studies that align with our established AOIs, we are also interested in supporting innovative research and studies involving diverse populations that contribute to real-world evidence and help inform clinical practice.

Search Functions
There are two ways to search on this page to narrow down the list of results:

Use the "Search Filters" on the left side of the page.
Use the "Search" box and enter keywords.

Search Clear All

7 Results:

Drug ↑	Title	Description	Created

Above Brand/Not Product Specific	Advancing Evidence in HIV Care: Not Product Specific (General)	ViiV Healthcare welcomes investigator-sponsored research that advances understanding of HIV care in a general context, without focusing on any specific product. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, quality of life, healthcare resource use, economic value, and health equity. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.	9/14/2025

Cabotegravir-PrEP	Advancing Evidence in Cabotegravir for HIV Prevention (General)	ViiV Healthcare welcomes investigator-sponsored research that advances understanding of cabotegravir in HIV prevention across a wide range of scientific priorities. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, quality of life, healthcare resource use, economic value, and health equity. We encourage innovative approaches and studies in diverse populations that can expand real-world knowledge and inform clinical practice.	9/14/2025

Cabotegravir-Treatment	Advancing Evidence in Cabotegravir Treatment (General)	ViiV Healthcare welcomes investigator-sponsored research that advances understanding of cabotegravir in HIV treatment across a wide range of scientific priorities. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, quality of life, healthcare resource use, economic value, and health equity. We encourage innovative approaches and studies in diverse populations that can expand real-world knowledge and inform clinical practice.	9/14/2025

Dolutegravir	Efficacy and Safety of DTG/3TC among Treatment-Naïve Individuals	ViiV Healthcare welcomes investigator-sponsored research that advances understanding of DTG/3TC in the treatment of HIV among treatment-naïve individuals. Research of interest may include real-world effectiveness, barrier to resistance, safety and tolerability, patient and provider experience, and health-related quality of life. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.	9/14/2025

Dolutegravir	Efficacy and Safety of DTG/3TC in Pregnancy	ViiV Healthcare welcomes investigator-sponsored research that advances understanding of the efficacy and safety of DTG/3TC in pregnancy. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, and health-related quality of life. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.	9/14/2025

Dolutegravir	Advancing Evidence in Dolutegravir/Lamivudine (DTG/3TC) Treatment (General)	ViiV Healthcare welcomes investigator-sponsored research that advances understanding of DTG/3TC in the treatment of HIV. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, and health-related quality of life. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.	9/14/2025

Other VH Products	Advancing Evidence in HIV Treatment: Using other VH Product besides Cabotegravir and Dolutegravir/Lamivudine (General)	ViiV Healthcare welcomes investigator-sponsored research that advances understanding of HIV treatment using other VH products besides Cabotegravir and Dolutegravir/Lamivudine. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, quality of life, healthcare resource use, economic value, and health equity. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.	9/14/2025

First 1 Last

7 Results:

Pure Substance Request

Investigator Sponsored Study (ISS)

Collaborative Study